Catálogo Taxonômico da Fauna do Brasil: setting the baseline knowledge on the animal diversity in Brazil

The limited temporal completeness and taxonomic accuracy of species lists, made available in a traditional manner in scientific publications, has always represented a problem. These lists are invariably limited to a few taxonomic groups and do not represent up-to-date knowledge of all species and classifications. In this context, the Brazilian megadiverse fauna is no exception, and the Catálogo Taxonômico da Fauna do Brasil (CTFB) (http://fauna.jbrj.gov.br/), made public in 2015, represents a database on biodiversity anchored on a list of valid and expertly recognized scientific names of animals in Brazil. The CTFB is updated in near real time by a team of more than 800 specialists. By January 1, 2024, the CTFB compiled 133,691 nominal species, with 125,138 that were considered valid. Most of the valid species were arthropods (82.3%, with more than 102,000 species) and chordates (7.69%, with over 11,000 species). These taxa were followed by a cluster composed of Mollusca (3,567 species), Platyhelminthes (2,292 species), Annelida (1,833 species), and Nematoda (1,447 species). All remaining groups had less than 1,000 species reported in Brazil, with Cnidaria (831 species), Porifera (628 species), Rotifera (606 species), and Bryozoa (520 species) representing those with more than 500 species. Analysis of the CTFB database can facilitate and direct efforts towards the discovery of new species in Brazil, but it is also fundamental in providing the best available list of valid nominal species to users, including those in science, health, conservation efforts, and any initiative involving animals. The importance of the CTFB is evidenced by the elevated number of citations in the scientific literature in diverse areas of biology, law, anthropology, education, forensic science, and veterinary science, among others

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK.

BACKGROUND: A safe and efficacious vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), if deployed with high coverage, could contribute to the control of the COVID-19 pandemic. We evaluated the safety and efficacy of the ChAdOx1 nCoV-19 vaccine in a pooled interim analysis of four trials. METHODS: This analysis includes data from four ongoing blinded, randomised, controlled trials done across the UK, Brazil, and South Africa. Participants aged 18 years and older were randomly assigned (1:1) to ChAdOx1 nCoV-19 vaccine or control (meningococcal group A, C, W, and Y conjugate vaccine or saline). Participants in the ChAdOx1 nCoV-19 group received two doses containing 5 × 1010 viral particles (standard dose; SD/SD cohort); a subset in the UK trial received a half dose as their first dose (low dose) and a standard dose as their second dose (LD/SD cohort). The primary efficacy analysis included symptomatic COVID-19 in seronegative participants with a nucleic acid amplification test-positive swab more than 14 days after a second dose of vaccine. Participants were analysed according to treatment received, with data cutoff on Nov 4, 2020. Vaccine efficacy was calculated as 1 - relative risk derived from a robust Poisson regression model adjusted for age. Studies are registered at ISRCTN89951424 and ClinicalTrials.gov, NCT04324606, NCT04400838, and NCT04444674. FINDINGS: Between April 23 and Nov 4, 2020, 23 848 participants were enrolled and 11 636 participants (7548 in the UK, 4088 in Brazil) were included in the interim primary efficacy analysis. In participants who received two standard doses, vaccine efficacy was 62·1% (95% CI 41·0-75·7; 27 [0·6%] of 4440 in the ChAdOx1 nCoV-19 group vs71 [1·6%] of 4455 in the control group) and in participants who received a low dose followed by a standard dose, efficacy was 90·0% (67·4-97·0; three [0·2%] of 1367 vs 30 [2·2%] of 1374; pinteraction=0·010). Overall vaccine efficacy across both groups was 70·4% (95·8% CI 54·8-80·6; 30 [0·5%] of 5807 vs 101 [1·7%] of 5829). From 21 days after the first dose, there were ten cases hospitalised for COVID-19, all in the control arm; two were classified as severe COVID-19, including one death. There were 74 341 person-months of safety follow-up (median 3·4 months, IQR 1·3-4·8): 175 severe adverse events occurred in 168 participants, 84 events in the ChAdOx1 nCoV-19 group and 91 in the control group. Three events were classified as possibly related to a vaccine: one in the ChAdOx1 nCoV-19 group, one in the control group, and one in a participant who remains masked to group allocation. INTERPRETATION: ChAdOx1 nCoV-19 has an acceptable safety profile and has been found to be efficacious against symptomatic COVID-19 in this interim analysis of ongoing clinical trials. FUNDING: UK Research and Innovation, National Institutes for Health Research (NIHR), Coalition for Epidemic Preparedness Innovations, Bill & Melinda Gates Foundation, Lemann Foundation, Rede D'Or, Brava and Telles Foundation, NIHR Oxford Biomedical Research Centre, Thames Valley and South Midland's NIHR Clinical Research Network, and AstraZeneca

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

Background A safe and efficacious vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), if deployed with high coverage, could contribute to the control of the COVID-19 pandemic. We evaluated the safety and efficacy of the ChAdOx1 nCoV-19 vaccine in a pooled interim analysis of four trials. Methods This analysis includes data from four ongoing blinded, randomised, controlled trials done across the UK, Brazil, and South Africa. Participants aged 18 years and older were randomly assigned (1:1) to ChAdOx1 nCoV-19 vaccine or control (meningococcal group A, C, W, and Y conjugate vaccine or saline). Participants in the ChAdOx1 nCoV-19 group received two doses containing 5 × 1010 viral particles (standard dose; SD/SD cohort); a subset in the UK trial received a half dose as their first dose (low dose) and a standard dose as their second dose (LD/SD cohort). The primary efficacy analysis included symptomatic COVID-19 in seronegative participants with a nucleic acid amplification test-positive swab more than 14 days after a second dose of vaccine. Participants were analysed according to treatment received, with data cutoff on Nov 4, 2020. Vaccine efficacy was calculated as 1 - relative risk derived from a robust Poisson regression model adjusted for age. Studies are registered at ISRCTN89951424 and ClinicalTrials.gov, NCT04324606, NCT04400838, and NCT04444674. Findings Between April 23 and Nov 4, 2020, 23 848 participants were enrolled and 11 636 participants (7548 in the UK, 4088 in Brazil) were included in the interim primary efficacy analysis. In participants who received two standard doses, vaccine efficacy was 62·1% (95% CI 41·0–75·7; 27 [0·6%] of 4440 in the ChAdOx1 nCoV-19 group vs71 [1·6%] of 4455 in the control group) and in participants who received a low dose followed by a standard dose, efficacy was 90·0% (67·4–97·0; three [0·2%] of 1367 vs 30 [2·2%] of 1374; pinteraction=0·010). Overall vaccine efficacy across both groups was 70·4% (95·8% CI 54·8–80·6; 30 [0·5%] of 5807 vs 101 [1·7%] of 5829). From 21 days after the first dose, there were ten cases hospitalised for COVID-19, all in the control arm; two were classified as severe COVID-19, including one death. There were 74 341 person-months of safety follow-up (median 3·4 months, IQR 1·3–4·8): 175 severe adverse events occurred in 168 participants, 84 events in the ChAdOx1 nCoV-19 group and 91 in the control group. Three events were classified as possibly related to a vaccine: one in the ChAdOx1 nCoV-19 group, one in the control group, and one in a participant who remains masked to group allocation. Interpretation ChAdOx1 nCoV-19 has an acceptable safety profile and has been found to be efficacious against symptomatic COVID-19 in this interim analysis of ongoing clinical trials

Corn yield with reduction of insecticidal sprayings against fall armyworm Spodoptera frugiperda (Lepidoptera: Noctuidae)

The ideal time is more important than amount of insecticidal spraying to adequate the control of Spodoptera frugiperda J.E. Smith (Lepidoptera: Noctuidae) in corn. This study aimed to evaluate lufenuron sequential sprayings effect and its rotation with other active ingredients on the population, damage caused by S. frugiperda and the impact on corn yield. The experiment was carried out in the field with six treatments: (1) one lufenuron spraying, (2) two lufenuron sprayings, (3) three lufenuron sprayings (4) four lufenuron sprayings, (5) sprayings with spinosad, lufenuron, thiamethoxam+lambdacyhalothrin and deltamethrin (in sequence, at ten days intervals) (6) control treatment. Sprayings started twenty days after the seedling had emerged and then every ten days for a maximum of four sprays. Both caterpillar population (20.9-21.7 larvae/plot) and index of damage (1.2-1.7) observed in corn plants were significantly lower in treated plots compared to control (untreated) (31.7 larvae/plot and index of damage 2.7), regardless of spraying amount. The results showed that multiple insecticide applications to control S. frugiperda do not guarantee higher yields in corn, ranging from 6375.2 to 7650.1 kg ha -1. Only one spraying of lufenuron was enough to prevent significant reduction in corn yield (6749.9 kg ha -1). © 2012 Asian Network for Scientific Information

Classificação espectral de área plantada com a cultura da cana-de-açúcar por meio da árvore de decisão Spectral classification of planted area with sugarcane through the decision tree

O objetivo deste trabalho foi testar o classificador "árvore de decisão", em dados provenientes de sensores orbitais, para identificar área plantada com cana-de-açúcar, em diferentes épocas de plantio na Fazenda Boa Fé, localizada no Triângulo Mineiro, mais especificamente no município de Conquista, Minas Gerais. Acoplaram-se técnicas de Sensoriamento Remoto (SR) em um módulo de Sistema de Informação Geográfica (SIG), permitindo uma análise temporal do uso e ocupação do solo, especialmente com vistas a identificar e a monitorar as áreas agrícolas. Com base no cálculo do viés médio (VM), o presente estudo mostrou que, em áreas de cana-de-açúcar, onde a irrigação é frequente e ocorrem chuvas significativas que antecedem a passagem do satélite Landsat-5, os valores foram ligeiramente subestimados, com valor deste indicador de -0,13 ha. Foi verificado, também, que os valores de NDVI mais altos proporcionaram uma leve superestimativa dos resultados, com valores de viés médio variando de 0,04 a 0,23 ha. Conforme os resultados, o classificador árvore de decisão apresentou um grande potencial para o mapeamento das áreas cultivadas com cana-de-açúcar.<br>This study was carried out to test the "decision tree" classifier via remote sensing (RS), to identify planted areas with sugarcane, at different planting dates in Boa Fé, located in the Triângulo Mineiro, more specifically in the town of Conquista, Minas Gerais, Brazil. RS techniques, integrated into a Geographic Information System (GIS), allow a temporal analysis of land use and occupation, especially in order to identify and monitor agricultural areas. Based on the calculation of mean bias (VM), this study showed that in areas of sugarcane, where irrigation is frequent and significant rainfall occurring prior to the passage of Landsat-5, the estimated values were slightly underestimated, with the value of this indicator equal to -0.13 ha. It was also verified that the highest values of NDVI provided a slight overestimation of the results, with values of mean bias of 0.04 to 0.23 ha. According to the results, the decision tree classifier had a great potential for mapping the areas cultivated with sugar cane